Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ecopipam in Adults With Childhood Onset Fluency Disorder
NCT04492956Phase 2Completed
- Sponsor
- Emalex Biosciences
- Start
- Oct 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in childhood-onset fluency disorder (COFD) comparing Ecopipam HCl ~2mg/kg/day with Matching Placebo (2 arms). Primary endpoint: Stuttering Severity Instrument, 4th Edition at 12 weeks. Started Oct 2020; status: completed.
02
Drugs
ecopipam
03
Conditions
childhood-onset fluency disorder (COFD)
Beyond the preview
Go deeper on NCT04492956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04492956.